PharmaEssentia Corporation
6446
株式のランク
#1442
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
株価
$36.89
時価総額
$15.25B
変化（1日）
-1.28%
変化（1年）
144.12%
国
TW
取引 PharmaEssentia Corporation (6446)
カテゴリー
Healthcare
PharmaEssentia Corporation（6446）のP/B比率
October 2026 時点のP/B比率 TTM: 13.50
PharmaEssentia Corporation の最新の財務報告および株価によると、現在のP/B比率（TTM）は 13.50 です。2023 年末時点でのP/B比率は 4.70 でした。
PharmaEssentia Corporation の P/B 比率の履歴（2010 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 13.50 | 85.23% |
| 2024 | 7.29 | 54.92% |
| 2023 | 4.70 | -57.85% |
| 2022 | 11.16 | -36.95% |
| 2021 | 17.70 | 205.50% |
| 2020 | 5.79 | -44.22% |
| 2019 | 10.39 | -30.22% |
| 2018 | 14.88 | 65.96% |
| 2017 | 8.97 | 16.17% |
| 2016 | 7.72 | -85.09% |
| 2015 | 51.79 | 198.70% |
| 2014 | 17.34 | 0.82% |
| 2013 | 17.20 | -64.44% |
| 2012 | 48.36 | -92.11% |
| 2011 | 613.14 | 490.71% |
| 2010 | 103.80 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -62.67% |
IN
|
